AN ORAL PCSK9 inhibitor significantly reduced low-density lipoprotein cholesterol (LDL-C) compared with existing oral non-statin therapies in a new Phase 3 trial, offering a promising alternative for patients not meeting lipid targets on statins alone.
Cardiovascular disease remains a leading global cause of mortality, with elevated LDL-C a key modifiable risk factor.
While statins form the backbone of lipid-lowering therapy, many patients require additional treatment to reach guideline-recommended targets.
Current oral non-statin options, such as ezetimibe and bempedoic acid, provide modest LDL-C reductions, leaving a clear unmet need for more potent, convenient therapies.
Oral PCSK9 Inhibitor Shows Superior LDL-C Reduction
In this randomised, double-blind trial, 301 statin-treated adults with established atherosclerotic cardiovascular disease or elevated risk were assigned to receive enlicitide, an oral PCSK9 inhibitor, or comparator oral therapies over 56 days. Participants were largely receiving moderate- to high-intensity statins, reflecting real-world clinical practice.
The oral PCSK9 inhibitor achieved a mean LDL-C reduction of -64.6% from baseline, substantially outperforming bempedoic acid (-6.3%), ezetimibe (-27.8%), and combination therapy (-36.5%). These differences were statistically significant across all comparisons (p<0.001).
Reductions in apolipoprotein B and non-high-density lipoprotein cholesterol followed a similar pattern, reinforcing the broad lipid-lowering efficacy of enlicitide.
Importantly, treatment completion rates were high (99.0%), and the incidence of adverse events and discontinuations was comparable across all groups, suggesting a favourable short-term safety profile.
Implications for Practice
These findings position the oral PCSK9 inhibitor as a potentially transformative option in lipid management, particularly for patients who fail to achieve LDL-C goals despite statin therapy.
Unlike injectable PCSK9 inhibitors, an oral formulation may improve accessibility, adherence, and patient acceptance.
However, several limitations warrant consideration.
The trial duration was relatively short at 56 days, meaning long-term efficacy, safety, and cardiovascular outcome benefits remain to be established. Additionally, while lipid reductions are strongly associated with improved outcomes, direct evidence of reduced cardiovascular events with enlicitide is still needed.
Nevertheless, the magnitude of LDL-C lowering observed suggests that oral PCSK9 inhibitor therapy could reshape treatment algorithms, bridging the gap between convenience and potency in lipid-lowering strategies.
Larger and longer-term studies will be critical to confirm its role in reducing cardiovascular risk and guiding its integration into routine care.
Reference
Catapano AL et al.; CORALreef AddOn Investigators. Oral PCSK9 inhibitor enlicitide versus oral non-statin therapies: a phase 3 randomized clinical trial. JACC. 2026;DOI:10.1016/j.jacc.2026.03.036.
Featured image: Jiraphong on Adobe Stock
